A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

Bowlus, Christopher L.; Galambos, Michael R.; Aspinall, Richard J.; Hirschfield, Gideon M.; Jones, David E. J.; Doerffel, Yvonne; Gordon, Stuart C.; Harrison, Stephen A.; Kremer, Andreas E.; Mayo, Marlyn J.; Thuluvath, Paul J.; Levy, Cynthia; Swain, Mark G.; Neff, Guy W.; Sheridan, David A.; Stanca, Carmen M.; Berg, Christoph P.; Goel, Aparna; Shiffman, Mitchell L.; Vierling, John M.; Boudes, Pol; Steinberg, Alexandra; Choi, Yun-Jung; McWherter, Charles A.

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

Author:

Bowlus, Christopher L.; Galambos, Michael R.; Aspinall, Richard J.; Hirschfield, Gideon M.; Jones, David E. J.; Doerffel, Yvonne; Gordon, Stuart C.; Harrison, Stephen A.; Kremer, Andreas E.; Mayo, Marlyn J.; Thuluvath, Paul J.; Levy, Cynthia; Swain, Mark G.; Neff, Guy W.; Sheridan, David A.; Stanca, Carmen M.; Berg, Christoph P.; Goel, Aparna; Shiffman, Mitchell L.; Vierling, John M.; Boudes, Pol; Steinberg, Alexandra; Choi, Yun-Jung; McWherter, Charles A.

Tübinger Autor(en):

Berg, Christoph Peter

Published in:

Journal of Hepatology (2022), Bd. 77, H. 2, S. 353-364

Verlagsangabe:

Elsevier

Language:

English

Full text:

http://dx.doi.org/10.1016/j.jhep.2022.02.033

ISSN:

0168-8278